Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and [1,4-13C2]fumarate

Aboagye EO, Bhujwalla ZM (1999) Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 59 (1): 80–84

Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K (2003) Increase in signal-to-noise ratio of >10 000 times in liquid-state NMR. Proc Natl Acad Sci USA 100 (18): 10158–10163

Aubin JE (1979) Autofluorescence of viable cultured mammalian cells. J Histochem Cytochem 27 (1): 36–43

Biersack HJ, Bender H, Palmedo H (2004) FDG-PET in monitoring therapy of breast cancer. Eur J Nucl Med Mol Imaging 31 (Suppl 1): S112–S117

Brindle K (2008a) New approaches for imaging tumour responses to treatment. Nat Rev Cancer 8 (2): 94–107

Brindle KM (2008b) Abstractions. Nature 453 (7197): xi

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (7035): 913–917

Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M (2000) Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 89 (11): 2145–2152

Day SE, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J, Golman K, Ardenkjaer-Larsen JH, Brindle KM (2007) Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med 13 (11): 1382–1387

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2): 228–247

Eubank WB, Mankoff DA (2005) Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 35 (2): 84–99

Fang Y, Sullivan R, Graham CH (2007) Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity. Exp Cell Res 313 (5): 867–877

Gallagher F, Kettunen M, Brindle K (2009a) Biomedical applications of hyperpolarized 13C magnetic resonance imaging. Prog NMR Spectrosc 55: 285–295

Gallagher FA, Kettunen MI, Day SE, Lerche M, Brindle KM (2008) 13C MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized 13C-labeled glutamine. Magn Reson Med 60 (2): 253–257

Gallagher FA, Kettunen MI, Hu DE, Jensen PR, Zandt RI, Karlsson M, Gisselsson A, Nelson SK, Witney TH, Bohndiek SE, Hansson G, Peitersen T, Lerche MH, Brindle KM (2009b) Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. Proc Natl Acad Sci USA 106 (47): 19801–19806

Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57 (7): 727–741

Gilles R, Guinebretiere JM, Toussaint C, Spielman M, Rietjens M, Petit JY, Contesso G, Masselot J, Vanel D (1994) Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 191 (3): 633–638

Glunde K, Jacobs MA, Bhujwalla ZM (2006) Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diag 6: 821–829

Hu JN, Feng WZ, Hua J, Jiang Q, Xuan Y, Li T, Haacke EM (2009) A high spatial resolution in vivo 1H magnetic resonance spectroscopic imaging technique for the human breast at 3 T. Medical Physics 36 (11): 4870–4877

Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB (2000) In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 6 (3): 880–886

Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG (1993) Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53 (17): 3976–3985

Krak NC, Hoekstra OS, Lammertsma AA (2004) Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations. Eur J Nucl Med Mol Imaging 31 (Suppl 1): S103–S111

Mason KA, Valdecanas D, Hunter NR, Milas L (2008) INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest New Drugs 26 (1): 1–5

Merchant TE, Obertop H, de Graaf PW (1993) Advantages of magnetic resonance imaging in breast surgery treatment planning. Breast Cancer Res Treat 25 (3): 257–264

Munoz-Gamez JA, Martin-Oliva D, Aguilar-Quesada R, Canuelo A, Nunez MI, Valenzuela MT, Ruiz de Almodovar JM, De Murcia G, Oliver FJ (2005) PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 386 (Part 1): 119–125

Neves AA, Brindle KM (2006) Assessing responses to cancer therapy using molecular imaging. Biochim Biophys Acta 1766: 242–261

Nuutinen J, Jyrkkio S, Lehikoinen P, Lindholm P, Minn H (1999) Evaluation of early response to radiotherapy in head and neck cancer measured with [11C]methionine-positron emission tomography. Radiother Oncol 52 (3): 225–232

Ollivier L, Balu-Maestro C, Leclere J (2005) Imaging in evaluation of response to neoadjuvant breast cancer treatment. Cancer Imaging 5 (1): 27–31

Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (10): 721–732

Smithers BM, Couper GC, Thomas JM, Wong D, Gotley DC, Martin I, Harvey JA, Thomson DB, Walpole ET, Watts N, Burmeister BH (2008) Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus 21 (2): 151–158

Strauss LG (1996) Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 23 (10): 1409–1415

Weissleder R, Pittet MJ (2008) Imaging in the era of molecular oncology. Nature 452 (7187): 580–589

Witney TH, Kettunen MI, Day SE, Hu DE, Neves AA, Gallagher FA, Fulton SM, Brindle KM (2009) A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia 11 (6): 574–582

Ying W, Alano CC, Garnier P, Swanson RA (2005) NAD+ as a metabolic link between DNA damage and cell death. J Neurosci Res 79 (1–2): 216–223

Zhuang H, Yu JQ, Alavi A (2005) Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am 43 (1): 121–134